Clover Biopharmaceuticals, a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, announced that enrollment of the first participants has been completed in a phase 2 clinical trial in Australia evaluating SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) protein-based vaccine candidates based on prefusion-stabilized F (PreF)-Trimer subunit vaccine antigens utilizing Clover’s validated Trimer-Tag vaccine technology platform.
“The initiation of this phase 2 trial for our respiratory combination vaccine candidates SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) further strengthens our global first-in-class potential,” said Joshua Liang, chief executive officer and board director of Clover. “This milestone builds upon our recent Phase 1 data indicating potential best-in-class RSV+hMPV±PIV3 combination vaccines with the potential ability to re-vaccinate individuals previously receiving approved RSV vaccines to restore and broaden protection, addressing multiple significant unmet needs globally.”
The ongoing phase 2 trial for Clover’s combination vaccine candidates is a randomized, observer-blinded, multi-center study enrolling up to 420 older adults (60-85 years) in Australia, and the participants will be randomized to receive either SCB-1022 (RSV + hMPV), SCB-1033 (RSV + hMPV + PIV3) or placebo. The study will assess safety, reactogenicity and immunogenicity.
